Navigating the Complexities of Minimal Residual Disease in Blood Cancers

The chapter delves into the controversies surrounding Minimal Residual Disease (MRD) measurement in blood cancers, discussing the evolution of MRD measurement technology and the implications of MRD negativity in disease monitoring and treatment decisions. It emphasizes the importance of eradicating residual disease at a cellular and molecular level to prevent relapse, highlighting the challenges in achieving and maintaining MRD negativity for long-term disease control. The conversation also touches on the timing of MRD negativity transitions in patients, individualized approaches based on disease specifics, and the challenges in designing prospective trials with MRD as a focal point in blood cancer treatment.